Trials / Completed
CompletedNCT05848206
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 251,831 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
Conditions
Timeline
- Start date
- 2022-03-11
- Primary completion
- 2022-04-29
- Completion
- 2022-04-29
- First posted
- 2023-05-08
- Last updated
- 2023-05-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05848206. Inclusion in this directory is not an endorsement.